Amgen (AMGN) is back in focus after its Q2 2026 report and raised full year guidance, which highlighted stronger earnings expectations and a pipeline that management presents as a key long term driver.

Amgen's share price has reacted strongly to the Q2 2026 earnings beat and raised guidance, with a 15.46% 1 month share price return and 27.02% year to date share price return, while the 5 year total shareholder return of 113.11% points to sustained long term gains and building momentum.

If Amgen's recent move has you thinking about other healthcare opportunities using AI, it could be a good moment to scan the market through the 43 healthcare AI stocks.

The earnings jump and guidance reset have pulled Amgen’s share price well above the average analyst target, while some models still suggest a sizeable discount to intrinsic value. Where does fair value really sit after this latest move?

Most Popular Narrative: 15.6% Overvalued

At a last close of $416.18 versus a narrative fair value of $359.98, Amgen screens as priced above the narrative's estimate and leans heavily on future execution.

The "Amgen 2027 Bull Case" relies on a classic top-line fallacy: assuming that macro obesity market growth and FDA's CNPV (Commissioner’s National Priority Voucher) tailwinds will automatically trigger a re-rating.

Here is the cold, data-driven reality:

Curious what sits behind that overvaluation call. The narrative leans on specific revenue growth, margin assumptions and a future earnings multiple. See which forecasts really carry the weight in this Amgen valuation story.

Result: Fair Value of $359.98 (OVERVALUED)

However, Amgen could still surprise if obesity assets scale faster than expected or if erosion in products such as Prolia and Enbrel stabilises sooner than feared.

Another View: Amgen Through the SWS DCF Model

The user narrative flags Amgen as 15.6% overvalued at $416.18 versus a $359.98 fair value. Our DCF model points in the opposite direction. It estimates fair value at $654.75, which is 36.4% above the current share price and frames Amgen as undervalued instead.

Two methods, two very different answers. One leans on market multiples and pipeline risk, and the other on future cash flows and high quality earnings. Which set of assumptions do you trust more when real money is on the line?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Amgen for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 49 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Mixed signals on Amgen's valuation and outlook are clear. Move quickly and review both sides of the story by checking the 4 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Amgen?

If Amgen has sharpened your focus, do not stop here. Broaden your watchlist with a few focused stock ideas that could bring different strengths to your portfolio.

• Target income potential by scanning for companies with resilient cash flows and higher yields through the 9 dividend fortresses.
• Spot opportunities that combine quality and attractive pricing when you review the 49 high quality undervalued stocks.
• Prioritise capital preservation and steadier profiles by checking stocks in the 85 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.